A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

PHASE3RecruitingINTERVENTIONAL

Enrollment

488

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

BL-B01D1

Administration by intravenous infusion

DRUG

Irinotecan

Administration by intravenous infusion

DRUG

paclitaxel

Administration by intravenous infusion

DRUG

docetaxel

Administration by intravenous infusion

Trial Locations (1)

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY